ClinicalTrials.gg
RecruitingNCT05240352Updated Feb 18, 2026

Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression

An interventional study of active tDCS and sham tDCS in Anhedonia, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Anhedonia with a site in United States — 24 open to participants now, 25 under way, none of them phase 3. Anhedonia · United States.

Planned enrollment
51st of 67
45 · median 70
Started
2022
with 9 others
No phase
42 of 76
19 open now
Primary completion
2026-12
later than 1 of 24 live
Registered
33rd of 76
by date

Among the 76 studies in Anhedonia with a site in United States, this one is the 51st largest by planned enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2022, is one of 42 with no phase, reaches primary completion later than 1 of the 24 other live ones, and was the 33rd registered.

Anhedonia

134 studies on the registry are indexed under Anhedonia; 50 are open to participants now.

Browse Anhedonia studies →

Open to participants now

24 of the 76 studies in Anhedonia with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Anhedonia studies recruiting now, 8 (19%) set no upper age limit and 33 (77%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Anhedonia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether transcranial direct-current stimulation (tDCS) will engage reward-related brain circuitry, more specifically the uncinate fasciculus (UF) tract, which connects the orbitofrontal cortex (OFC) and nucleus accumbens (NAcc) regions. Also to evaluate whether the changes in the fractional anisotropy (FA) of the UF tract are associated with changes of clinical symptoms of anhedonia and finally to investigate the moderation role of simulated electric fields (EFs) in an association between FA of the UF and symptoms of anhedonia.

03

Conditions studied

  • Anhedonia

Keywords

  • bipolar depression
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of Bipolar Disorder and anhedonia
  • mild symptoms of depression

Exclusion criteria

Exclusion Criteria:

  • substance abuse/dependence and any use of drugs (except alcohol or nicotine) in the previous month of the baseline assessment
  • participants with personality disorder that would interfere with study participation according to clinical judgment
  • previous neurological conditions (epilepsy, traumatic brain injury, stroke, etc)
  • any severe, life-threatening non-psychiatric medical condition
  • specific for tDCS (metallic plates in the head)
  • Participants identified as acutely suicidal or severely agitated
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    active tDCS

    Device: active tDCS

  • Sham comparator
    sham tDCS

    Device: sham tDCS

Interventions

  • Deviceactive tDCS

    Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later

  • Devicesham tDCS

    Subjects will receive a dose from a "sham-tDCS"that is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later

06

What researchers measure

Primary outcomes

  1. change in the fractional anisotropy of the uncinate fasciculus

    Change in the fractional anisotropy of the uncinate fasciculus as assessed by diffusion tensor imaging (DTI)

    Time frame: baseline, 6 weeks

Secondary outcomes

  1. changes in symptoms of anhedonia as assessed by the Snaith-Hamilton Pleasure Scale modified for clinical administration (SHAPS-C)

    This is a 14 item questionnaire and each is scored from 1 to 4 (1 = Lots of pleasure, 4 = No pleasure)

    Time frame: baseline, 6 weeks

  2. change in symptoms of anticipatory anhedonia as assessed by the Temporal Experience of Pleasure Scale (TEPS)

    The TEPS presents 18 items, 10 of them related to the experience of anticipatory pleasure, and the other 8 related to the ability to experience pleasure at the moment. This is scored on a 6-point Likert scale (1 = very false for me to 6 = very true for me).Total scores vary form 18-108 and lower scores mean higher anhedonia

    Time frame: baseline, 6 weeks

  3. change in symptoms of consummatory anhedonia as assessed by the Temporal Experience of Pleasure Scale (TEPS)

    The TEPS presents 18 items, 10 of them related to the experience of anticipatory pleasure, and the other 8 related to the ability to experience pleasure at the moment. This is scored on a 6-point Likert scale (1 = very false for me to 6 = very true for me).Total scores vary form 18-108 and lower scores mean higher anhedonia

    Time frame: baseline, 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.

Of 58 non-industry interventional studies with no phase under Anhedonia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 46. This study's planned 49 months is above that.

Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 14 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2022
First posted
Feb 15, 2022
StartActual
Oct 6, 2022
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05240352
Collaborators
Milken Institute
Responsible party
Jair Soares (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Feb 15, 2022
Start date
Oct 6, 2022
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Jair C Soares, MD,PhD
Contact
UTMoodDisorders@uth.tmc.edu
(713) 486-6663
Alexandre P Diaz, MD,PhD
Contact
UTMoodDisorders@uth.tmc.edu
(713) 486-6663
Jair C Soares, MD,PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion